Body's Own Opioid Peptides Show Biased Signaling at the Mu Receptor — Implications for Safer Pain Drugs

Endomorphin-1 and endomorphin-2 showed a bias toward cAMP signaling at the mu opioid receptor (MOR), while dynorphin-B showed a bias toward G-protein (35S-GTPgammaS) signaling. This pattern was consistent across multiple cell lines expressing human MOR.

The researchers investigated whether RGS-4 (a G-protein regulator) or adenylyl cyclase 6 (AC6) might explain the endomorphin bias. However, neither an RGS-4 inhibitor nor AC6 knockdown significantly changed the bias profile, ruling out these specific mechanisms.

Biased agonism at opioid receptors is important because different signaling pathways may lead to different physiological effects. Pain relief, euphoria, respiratory depression, and constipation are thought to be mediated by different downstream pathways.

Understanding biased agonism at opioid receptors could help develop pain medications that relieve pain without causing dangerous side effects like respiratory depression. If the body's own peptides already show signaling bias, that bias may be harnessable for drug design.

The finding that endogenous peptides have built-in bias challenges the simple view that all opioid agonists act the same way at the same receptor.

This was entirely a cell-based study using overexpression systems, which may not fully reflect signaling in neurons. The functional consequences of the observed bias in terms of pain, reward, or side effects were not tested.

The mechanisms underlying the bias remain unclear after ruling out RGS-4 and AC6.